Floatz logo

Kup-101A

Mucosal Melanoma

Kupando GmbHPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

32 Active assets in the Mucosal Melanoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Melanoma Institute Australia
Phase 3BB
Tyrosinase Peptide
University of Southern California
Phase 3BB
INTERFERON ALFA-2B
Shanghai Junshi Bioscience Co., Ltd.
Phase 3B
Ifa
Craig L Slingluff, Jr
Phase 2B
Carboplatin
Sun Yat-sen University
Phase 3B

View all 50 →

Same molecule, other indications

Kup-101A is also rated in:

cutaneous neuroendocrine carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
skin squamous cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
cutaneous melanomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →